Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Soligenix Inc (SNGX)

Soligenix Inc (SNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,296
  • Shares Outstanding, K 10,086
  • Annual Sales, $ 120 K
  • Annual Income, $ -8,270 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 2.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.47

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0200 +9.80%
on 02/05/26
1.4600 -23.29%
on 01/22/26
-0.2300 (-17.04%)
since 01/09/26
3-Month
1.0200 +9.80%
on 02/05/26
1.6950 -33.92%
on 12/12/25
-0.2400 (-17.65%)
since 11/10/25
52-Week
1.0200 +9.80%
on 02/05/26
6.2299 -82.02%
on 08/18/25
-1.2300 (-52.34%)
since 02/10/25

Most Recent Stories

More News
Soligenix’s (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach

Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed the company’s release of positive top-line results from its phase 2 clinical trial evaluating SGX945 for the treatment of aphthous...

SNGX : 1.1200 (unch)
Soligenix (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer

Cutaneous T-cell lymphoma (“CTCL”) remains a cancer with limited treatment options, persistent symptoms and long-term quality-of-life challenges for patients, even decades after its classification...

SNGX : 1.1200 (unch)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape

As the global burden of rare diseases continues to rise, there is increasing urgency for innovative therapies that address unmet medical needs. More than 300 million people worldwide live with one or more...

SNGX : 1.1200 (unch)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM)

Cutaneous T-cell lymphoma, or CTCL, is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages. A recent article discussed Soligenix’s (NASDAQ: SNGX)...

SNGX : 1.1200 (unch)
RiVax(R) Positions Soligenix (NASDAQ: SNGX) in Growing Biodefense Preparedness Efforts

Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, was featured in a recent article discussing its development of a vaccine candidate known as RiVax(R) to protect against...

SNGX : 1.1200 (unch)
Soligenix (NASDAQ: SNGX) Announces Positive Phase 2 Data for Rare Inflammatory Disease

Behçet’s disease is a rare, chronic inflammatory condition that can cause recurrent, painful ulcers, eye inflammation and systemic complications that significantly affect quality of life. Because available...

SNGX : 1.1200 (unch)
Soligenix (NASDAQ: SNGX) Advances Solutions for Hard-to-Diagnose CTCL

Cutaneous T-cell lymphoma, or CTCL, is a rare form of non-Hodgkin lymphoma that primarily affects the skin, often presenting with symptoms that closely resemble common dermatologic conditions such as eczema...

SNGX : 1.1200 (unch)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte(TM)

Soligenix (NASDAQ: SNGX) is a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need. The company recently received updated...

SNGX : 1.1200 (unch)
Soligenix (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat

A recent “Times of India” report spotlighted the danger posed by ricin, a highly toxic plant-derived compound with no known antidote and a history of attempted misuse by extremist actors. Soligenix...

SNGX : 1.1200 (unch)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease

Soligenix (NASDAQ: SNGX) announced that results from its Phase 2a proof-of-concept study evaluating SGX945 (dusquetide) for the treatment of aphthous ulcers associated with Behçet’s Disease have been...

SNGX : 1.1200 (unch)

Business Summary

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable...

See More

Key Turning Points

3rd Resistance Point 1.1800
2nd Resistance Point 1.1680
1st Resistance Point 1.1440
Last Price 1.1200
1st Support Level 1.1080
2nd Support Level 1.0960
3rd Support Level 1.0720

See More

52-Week High 6.2299
Fibonacci 61.8% 4.2397
Fibonacci 50% 3.6249
Fibonacci 38.2% 3.0102
Last Price 1.1200
52-Week Low 1.0200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar